Dr. Suresh Ramalingam on sequencing immune checkpoint inhibitors with chemotherapy in NSCLC treatment. He adds that a new class of agents can be given in conjunction with immune checkpoint inhibitors, such as IDO inhibitors.
Suresh Ramalingam, MD, director of Medical Oncology and Lung Cancer Program, Winship Cancer Institute of Emory University, on sequencing immune checkpoint inhibitors with chemotherapy in non-small-cell lung cancer (NSCLC) treatment. He adds that a new class of agents can be given in conjunction with immune checkpoint inhibitors, such as IDO inhibitors.
Ramalingam says that with recent developments in immune checkpoint inhibitors, community oncologists may see them move from second-line treatment in NSCLC to earlier treatments. He says this may help improve cure rates within the stages of metastatic disease.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More